, Tracking Stock Market Picks
Enter Symbol:
Cadence Pharmaceuticals, Inc. (CADX) [hlAlert]

up 130.31 %

Cadence Pharmaceuticals, Inc. (CADX) rated Buy with price target $14 by Wedbush Morgan

Posted on: Wednesday,  Mar 11, 2009  9:25 AM ET by Wedbush Morgan

Wedbush Morgan rated Buy Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) on 03/11/2009, when the stock price was $6.07. Since
then, Cadence Pharmaceuticals, Inc. has gained 130.31% as of 03/18/2014's recent price of $13.98.
If you would have followed this Wedbush Morgan's recommendation on CADX, you would have gained 130.31% of your investment in 1833 days.

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/11/2009 9:25 AM Buy
6.07 14.00
as of 12/31/2009
1 Week down  -25.77 %
1 Month down  -16.18 %
3 Months down  -34.90 %
1 YTD up  18.61 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy